Fudan University

Scientists identified 18 genes influencing tooth size and shape, including a Neanderthal gene found in Europeans, which impacts incisor thickness. The findings, published in 'Current Biology', could aid dental health through genetic testing and potential gene therapies.

Two trials of neoadjuvant immunotherapy for TNBC showed mixed efficacy signals. NSABP B-59/GBG-96-GeparDouze found no EFS improvement with atezolizumab despite higher pCR. CamRelief trial showed significant pCR improvement with camrelizumab but no survival endpoint advantages. Both trials highlighted the need for further research on biomarkers for patient selection.

Neoadjuvant camrelizumab plus chemotherapy significantly improved pathologic complete response (pCR) rates over chemotherapy alone in early or locally advanced triple-negative breast cancer (TNBC), with a 12.2% difference (95% CI, 3.3%-21.2%; 1-sided P = .0038). The phase 3 CamRelief study also showed a trend toward improved survival, supporting camrelizumab plus chemotherapy as a potential new neoadjuvant therapeutic option for TNBC.

The phase 3 CamRelief study showed a 56.8% pathologic complete response rate for camrelizumab plus chemo vs 44.7% for chemo alone in early or locally advanced TNBC, with consistent benefits across subgroups. Early survival trends also favored the camrelizumab regimen.

Camrelizumab plus intensive chemotherapy in neoadjuvant setting improved pathologic complete response (pCR) rates vs chemotherapy alone in early or locally advanced triple-negative breast cancer (TNBC), with a 12.2% difference (56.8% vs 44.7%). Early trends in survival outcomes also favored the camrelizumab regimen.

BioNTech plans to advance BNT327 to Phase III for triple-negative breast cancer after promising Phase II survival data. BNT327, a PD-L1 x VEGF bispecific, showed 13.5 months of progression-free survival when combined with nab-paclitaxel as first-line therapy for locally advanced or metastatic TNBC.

China's NEO brain-computer interface (BCI) device, developed by Shanghai Neuracle Medical, will undergo large-scale clinical trials in 2025, aiming for regulatory approval. The trials will focus on spinal cord injury patients, with successful surgeries already demonstrating improved mobility. NEO is the first Chinese BCI to enter a Special Review Procedure for Innovative Medical Devices.

A 38-year-old spinal cord patient in Shanghai, unable to stand and with lost hand function since a car accident, received a Neural Electronic Opportunity (NEO) implant, a collaboration between Neuracle Technology and Tsinghua University. The results exceeded expectations, according to Mao Ying, head of the National Centre for Neurological Disorders and director of Huashan Hospital.

Investigated acupuncture intensity's impact on analgesic effects in AA rat models, finding optimal frequency (1.0 Hz) and amplitude (1.0~1.5 mm) for best outcomes, correlated with mast cell degranulation.

Cerba Research shared recent cell and gene therapy developments at the 31st ESGCT Congress, highlighting advancements in genome editing for cholesterol management and hearing restoration in children. CAR T-cell therapies for autoimmune diseases and innovations in treatment monitoring were also discussed, emphasizing the rapid integration of technology and AI in gene therapy development.